Ten years ago, scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, had developed an experimental vaccine designed to spur production of antibodies against a key malaria parasite protein, AMA1. It showed promise in test-tube and animal experiments and in early-stage clinical trials, but returned disappointing results in recent human trials conducted in malaria-endemic countries. Now, ...
Read More
No comments:
Post a Comment